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Benzimidazole nucleus considered as an important scaffold for developing drug candidates against a wide spectrum of 
diseases. Adenosine deaminase (ADA), an enzyme present in purine metabolic pathway, has a significant role in 
inflammatory and malignant diseases and hence it is considered as a major target for drug development. The present study 
investigates ADA inhibitory potential of selected benzimidazole derivatives by using in silico and in vitro methods. 
Molecular docking and dynamics simulations have been carried out to identify potential ADA activesite binders from 
benzimidazole derivatives. Compounds having strong binding affinities were selected for enzyme inhibition assays and 
fluorescent binding studies. The results showed that the pyridinyl and butyl derivatives of benzimidazole possess significant 
ADA inhibitory potential.The study proposes these compounds can be used as potent candidates for developing ADA 
inhibitor drugs.  
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Benzimidazoles are hetercyclic organic compounds 
containing imidazole moiety fused to benzene ring. 
Benzimidazole is an important pharmacophore and a 
privileged scaffold in medicinal chemistry1. It has 
been observed that, drugs belonging to different 
groups such as antimicrobials, antioxidants, anti-
inflammatory, immunomodulators, and antidiabetics 
contain benzimidazole moiety. Thiabendazole, 
flubendazole (anthelmintic), astmizole (antihistaminic), 
lansoprazole and omeprazole (antiulcerative) are 
some examples of marketedbenzimidazole drugs.  
Adenosine deaminase (ADA), also known as 
adenosine aminohydrolase, is a key enzyme involved 
in the conversion of adenosine to inosine irreversibly2. 
ADA is a zinc containing metalloenzyme present in 
both prokaryotes and eukaryotes. In humans, ADA is 
normally present in all tissues, highest activity 
observed in lymphoid system3, 4. ADA plays a crucial 
role in adenosine homeostasis and nucleic acid 
metabolism. The binding of ADA with CD26 and 
adenosine receptors triggers immune responses and 
various cellular activities5-7. Deficiency of the enzyme 
leads to severe combined immune deficiency (SCID)8. 
Over-activity of ADA leads to inflammation and 
certain types of cancers9, 10. The interaction of 
extracellular form of ADA (ecto-ADA) with CD2611 
regulates T cell activation and chronic inflammation 
by metabolizing extracellular adenosine released at 
inflamed sites, which are toxic to lymphocytes12.  
The role in regulating immune responses and 
cell growth make ADA a potential drug target 
against various diseases. Moreover ADA inhibitors 
getting increased attention as immuno-suppressants13. 
Due to the involvement of ADA in various 
pathogenesis, its inhibitors are being considered as 
promising candidates for the development of anti-
inflammatory, anti-proliferative and immune-
suppressant drugs14. 
Till date numerous ADA inhibitors have been 
reported from natural and synthetic sources. Most of 
them have several drawbacks including toxicity, low 
potency and poor pharmacokinetics. The main 
objective of the current study was to investigate 
ADA inhibitory potential of some benzimidazole 
derivatives by using in silico and in vitro methods. 
Materials and Methods 
Docking Studies 
The ADA active site binding property of 
benzimidazole derivatives was studied by in silico 
methods. Schrodinger suite (Maestro) was used for 
the molecular docking studies15. The crystal structure 
of bovine ADA in complex with EHNA (pdb 
ID:2Z7G) from PDB was used as the protein input 
structure. The structure was prepared for docking 




studies using the protein preparation wizard of 
Schrodinger software using OPLS_3 force field16. A 
grid of dimension 12 Å was generated around the 
bound ligand, EHNA in the crystal structure in such a 
manner that it could cover the entire active site cleft. 
The structure data files (SDF) of benzimidazole 
derivatives were downloaded from ZINC database 
(http://zinc.docking.org/). The downloaded ligand files 
were prepared using ligprep module of Schrodinger 
suite. Docking simulations were carried out using extra 
precision (XP) method of glide module. 
 
Molecular Dynamics 
MD simulations were conducted using Desmond 
module of Schrödinger (Schrödinger, LLC, New 
York) to assess the binding stability of 
benzimidazole derivatives at the active site of 
ADA17. The high scored ligand docked ADA 
complexes, were used as the initial structure for MD 
studies. An orthorhombic water box was generated 
in such a way that it covers the entire protein-ligand 
complex using TIP3P solvent model. Based on the 
charges of each complex, sodium or chloride ions 
were added accordingly to neutralize the charge of 
complexes. The solvated systems for molecular 
dynamics were generated using system builder 
option in Desmond module. After system generation, 
minimization and relaxation of the protein-ligand 
complex under NPT ensemble,was carried out using 
default protocol of Desmond module. This process 
includes a total of 9 stages among which there are  
2 minimization and 4 short simulations (equilibration 
phase) steps before starting the actual production 
time. 
The stages that includes in MD run; 
Stage 1 – task 
stage 2 - minimize, Minimization with restraints on 
solute 
stage 3 - minimize, Minimization without any 
restraints 
stage 4 - simulate, Berendsen NVT, T = 10 K, 
small timesteps, and restraints on solute.heavy atoms 
stage 5 - simulate, Berendsen NPT, T = 10 K, and 
restraints on solute heavy atoms 
stage 6 - solvate_pocket 
stage 7 - simulate, Berendsen NPT and restraints 
on solute heavy atoms 
stage 8 - simulate, Berendsen NPT and no 
restraints 
stage 9 – simulate 
Molecular dynamic simulations were conducted 
with the periodic boundary conditions in the NPT 
ensemble using OPLS_3 force field parameters. The 
temperature and pressure were kept at 300 K and 1 
atmospheric pressure respectively using Nose-Hoover 
temperature coupling and isotropic scaling18. The 
operation was followed by running the 30 ns NPT 
production simulation. 
 
Enzyme inhibition assay 
ADA (bovine), Benzimidazole derivatives and 
adenosine were purchased from Sigma Aldrich. The 
ADA inhibitory activity of selected benzimidazoles 
was determined through Berthelot reaction19. In this 
reaction, ADA converts adenosine to inosine and 
produce ammonia. This ammonia reacts with  
phenol and sodium hypochlorite to form indophenol. 
The quantity of indophenol was determined 
spectrophotometrically by measuring the optical 
density (OD) at 635 nm. The reaction was initiated by 
the addition of 10 µL enzyme solution (0. 40 units/ml) 
to the reaction mixture prepared in the 50 mM 
potassium phosphate buffer of pH 7.4 containing  
20 µM adenosine. After five minutes, the reaction  
was stopped by the addition of 400 µL phenol-
nitroprusside solution. To this solution 500 µL of 
sodium hypochlorite in 0.6 M NaOH was added and 
incubated for 30 minutes. The OD at 635 nm was 
measured using a UV spectrophotometer (Thermo 
Fisher Scientific, MA, USA). A solution without the 
enzyme was taken as the blank for the measurement 
of OD. EHNA (erythro-9-(2-hydroxy-3-nonyl) 
adenine), a potent inhibitor of ADA was used as 
positive control. The ADA activity was expressed in 
micromoles of ammonia liberated in one minute. The 
assay was repeated in triplicate under same 
conditions. The enzyme kinetics studies were carried 
out with different substrate concentrations (10-60 
µM). The Lineweaver-Burk plot was drawn and 
Michaelis-Menten constant (Km) and Maximal 
Velocity (Vmax) were determined from the graph. 
 
Fluorescence spectroscopy  
The interaction of benzimidazole derivatives with 
ADA active site was studied using Fluorescence 
spectroscopy with varying ligand concentration. 
Fluorescence measurements were carried out using 
HORIBA FluoromaxSpectrofluorometer (Kyoto, 
Japan) with a fluorescence cuvette of 1.0 cm path 
length. The fluorescence emission of bare ADA and 




that with different concentrations of the ligands were 
recorded at room temperature. Excitation wavelength 
was set as 290 nm and emission was scanned every 1 
nm in the range of 300 nm to 400 nm 
 
Results and Discussion  
 
Computational screening of ADA inhibitors 
The in silico docking studies revealed that  
some compounds among the screened 
benzimidazolederivatives have the potential to be 
ADA inhibitors. Three such compounds, 1,3-Dihydro-
1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazole-
2-one (Zinc ID: 394330), 1-Butyl-1H-benzoimidazol-
2-ylamine (Zinc ID: 2475956) and 1-Benzyl-1H-
benzoimidazol-2-ylamine (Zinc ID : 132982) were 
selected for further studies. The molecular structures 
and binding scores are shown in Table I.  
Zn 394330, benzimidazole derivative with 
pyridinyl ring, showed the highest binding affinity 
towards ADA active site. The compound formed 
hydrogen bond with the enzyme residue Asp 16 and 
pi-pi staking interaction with Phe 58. The glide score 
obtained was -7.267 Kcal/mol. Another selected 
benzimidazole derivative having a butyl chain, Zn 
2475956, showed a glide score -6.43 Kcal/mol. This 
compound formed hydrogen bonds with the residues 
Asp 16 and Asp 293. The third selected derivative,  
Zn 132982 madehydrogen bonds with residues  
Gly 181 and Glu 214. The glide score for binding was  
-4.786 Kcal/mol.  
 
Molecular Dynamics 
The binding stability of top scored benzimidazole 
derivatives at ADA active site was assessed through 
molecular dynamics studies by using Desmond 
module of Schrodinger software. The deviation from 
initial structure was expressed in terms of Root Mean 
Square Deviation (RMSD). The results showed that 
the binding of the compounds with ADA were stable 
and no drastic change from the initial position was 
observed during the 30 ns MD run (Figure 1). The 
RMSD observed was below 3 Å. The ADA-Zn 
Table I ― The molecular structures and binding scores of the 
selected benzimidazole derivatives. 








with the ligands 
Zn 394330 
 
-7.267 Asp 16 
Zn 2475956 
 
-6.43 Asp 16, Asp 293 
Zn 132982 
 




Figure 1 ― Protein (top) and ligand (bottom) RMSD change
observed for each complex, Zn 394330 (a), Zn 2475956(b) and
Zn 132982 (c) during 30 ns MD run. 
 




394330 complex was very stable during the 
simulation with an RMSD below 1.8 Å for the protein 
and 0.5 Å for the ligand (Figure 1a). The 
intermolecular hydrogen bond with Asp 16 existed 
throughout the simulation time (Figure 2).  
The complex with Zn 2475956, showed protein 
RMSD around 1.6 Åand ligand RMSD around 1.2 Å 
(Figure 1b). The hydrogen bonds that stabilized the 
binding, Asp 16 and Asp 293 were found to be stable 
during the MD run (Figure 3). The RMSDs for 
protein and ligand were 2 Å and 1.5Årespectively in 
the case of ADA-Zn 132982 complex (Figure 1c). 
The binding of Zn 132982 at ADA active site was 
mainly stabilized by hydrophobic interactions 
involving the phenyl ring. The majority of these 
hydrophobic interactions existed during MD run 
(Figure 4).  
 
ADA inhibition assay 
ADA inhibitory activity of the selected 
benzimidazole derivatives was analyzed by Berthelot 
 
 
Figure 2 ― Interaction details of Zn 394330 with ADA active site
during the course MD simulation. (a) Protein interactions with the
ligand (Zn 394330) monitored during the MD run. The y axis
value 1 indicates that 100 % of the simulation time the specific
interaction is maintained. Values over 1.0 are possible as some
protein residue may make multiple contacts with the ligand. (b)
Schematic diagram of detailed ligand atom interactions with the
protein residues and percentage of time each contact retained
during the simulation time. (c) A timeline representation of the
interactions and contacts observed with 394330 and ADA in each
trajectory frame during the MD run. 
 
 
Figure 3 ― Interaction details of Zn 2475956 with ADA active
site during the course MD simulation. (a) Protein interactions with
the ligand (Zn 2475956) monitored during the MD run. The y axis
value 1 indicates that 100 % of the simulation time the specific
interaction is maintained. Values over 1.0 are possible as some
protein residue may make multiple contacts with the ligand. (b)
Schematic diagram of detailed ligand atom interactions with the
protein residues and percentage of time each contact retained
during the simulation time. (c) A timeline representation of the
interactions and contacts observed with Zn 2475956 and ADA in
each trajectory frame during the MD run. 




reaction. EHNA, the standard ADA inhibitor was 
used as the positive control. The compound  
Zn 394330 showed highest inhibition on ADA 
activity (Figure 5). The percentage of inhibition was 
found to be 72. Zn 2475956 showed moderate 
inhibition (39 %) and Benzyl-1H-benzoimidazol-2-
ylamine (Zn 132982) showed weak inhibition (around 
10 %) (Figure 6). The assay results showed that the 
benzimidazole with pyridinylring (Zn 394330) is a 
strong inhibitor of ADA while the butyl derivative 
(Zn 2475956) is only a moderate inhibitor. The benzyl 
derivative (Zn 132982) did not show any significant 
inhibition on ADA activity (Table II). 
The kinetics of inhibition was studied using 
different concentration of substrates (adenosine) 
ranging from 10 to 60 μM. From the kinetics assay 
results, Lineweaver–Burk graph was plotted and Km, 
K'm (altered km) and Ki (inhibitor constant) values 
were determined. The compound Zn 394330 exhibited 
competitive mode of inhibition. The Ki value was 
determined as 20.83 μM (Figure 6). The compound 
Zn 2475956 also showed competitive type of 
inhibition and Ki obtained was 149.96 μM (Figure 7). 
 
 
Figure 4 ― Interaction details of Zn 132982 with ADA active site
during the course MD simulation. (a) Protein interactions with the
ligand (Zn 132982) monitored during the MD run. The y axis
value 1 indicates that 100 % of the simulation time the specific
interaction is maintained. Values over 1.0 are possible as some
protein residue may make multiple contacts with the ligand. (b)
Schematic diagram of detailed ligand atom interactions with the
protein residues and percentage of time each contact retained
during the simulation time. (c) A timeline representation of the
interactions and contacts observed with Zn 132982 and ADA in




Figure 5 ― ADA inhibitory activity of Zn 394330 (a),




Figure 6 ― Lineweaver–Burk plot of normal reaction and Zn
394330 inhibited reaction 
 






Figure 7 ― Lineweaver–Burk plot of normal reaction and Zn 
394330 inhibited reaction. 
 
Table II ― Inhibitor Constant (Ki) calculated from enzyme 
kinetics study. 
Compound  Inhibitor Constant ( Ki) μM 
Pyridinylbenzimidazole (Zn 394330) 20.83 
Butyl benzimidazole (Zn 2475956) 149.96 
 
Fluorescence spectroscopy 
The interaction of inhibitors with ADA active site 
was studied using tryptophan fluoresce quenching 
studies. The active site of ADA contains two 
tryptophan residues, Trp 114 & Trp 15820, 21 and the 
interaction of these tryptophan residues with inhibitor 
on binding will lead to the quenching (reduction) of 
fluorescence intensity. The study was conducted with 
bare ADA and ADA with different concentration of 
ligands. The protein was excited at 290 nm and 
emission was recorded. As the concentration of ligand 
increases (2-20μM) the emission spectrum showed a 
remarkable decrease inthe fluorescence emission 
(Figure 8). This concentration dependent decrease in 
the fluorescence indicated that the study results 
showed that pyridine derivative of Benzimidazole (Zn 
394330) is a very strong binder of active site.  
The butyl derivative (Zn 394330) also showed 
significant quenching of ADA fluorescence, but not 
as strong as that of the pyridine derivative (Figure 9). 
The benzylbenzimidazole (Zn 132982) didn’t show 
any significant quenching and hence a weak binder to 
ADA active site (Figure 10). 
From the fluorescence emission spectrum data the 
Stern-Volmer plots were generated for pyridinyl  
and butyl derivatives using F0/F values and  
ligand concentration. F0 and F correspond to the 
fluorescence intensities of the protein without 
 
 
Figure 8 ― Fluorescence emission spectra of ADA with 





Figure 9 ― Fluorescence emission spectra of ADA with
increasing concentration of Zn 2475956 (8- 48 μM) on excitation 




Figure 10 ― Fluorescence emission spectra of ADA with 
increasing concentration of Zn 132982 (8- 56 μM) on excitation 
at 280 nm 




quencher (ligand) and with quencher respectively. 
Stern−Volmer Constants (Ksv), which represent the 
binding affinity between the quencher (ligand) and 
fluorophore (protein), were determined the slopes  
of the plots (Figure 11). Pyrdynylbenzimidazole 
derivative (Zn 394330) showed high Ksv value (14.02 
× 10 6 M-1) than the butyl benzimidazole derivative 
(0.015× 10 6 M-1) (Table III). In agreement with the 
enzyme inhibition studies, fluorescent quenching 
studies showed that Pyrdynylbenzimidazole (Zn 
394330) with high binding affinity, butyl 
benzimidazole (Zn 2475956) has moderate affinity 
and benzyl benzimidazole (Zn 132982) with 
negligible binding affinity to ADA. 
 
Conclusion 
Benzimidazoles have wide applications in 
medicinal chemistry and it is considered as an 
important scaffold for developing therapeutic agents 
against many diseases. ADA inhibitory activity  
of some benzimidazole derivatives have been  
studied using in silico and in vitro methods.  
Three compounds, 1,3-Dihydro-1-(1,2,3,6-tetrahydro-
4-pyridinyl)-2H-benzimidazole-2-one (Zinc ID: 
394330), 1-Butyl-1H-benzoimidazol-2-ylamine (Zinc 
ID: 2475956) and 1-Benzyl-1H-benzoimidazol-2-
ylamine (Zinc ID : 132982) were selected based on  
in silicostudies and used for further in vitro studies. 
The inhibition assay showed that pyridinyl derivative 
is a strong inhibitor of ADA activity (Ki 20 μM), 
butyl derivative is a moderate inhibitor (Ki 149 μM) 
and benzyl derivative showed no inhibition. The 
binding studies using spectrofluorometry confirmed 
the active site binding potential of the first two 
compounds. The current study proposes 1,3-Dihydro-
1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazole-
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